Niraparib companion diagnostic - Myriad Genetics
Alternative Names: BRACAnalysis (Niraparib); Niraparib - BRACAnalysis; Niraparib - BRACAnalysis CDxLatest Information Update: 02 Jan 2023
At a glance
- Originator Myriad Genetics
- Developer GSK; Myriad Genetics; TESARO
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 02 Jan 2023 Launched for Breast cancer (Diagnosis) in USA (Myriad Genetics pipeline, January 2023)
- 28 Sep 2020 No development reported - Phase-III for Breast cancer (Diagnosis) in United Kingdom, Spain, Portugal, Poland, Netherlands, Italy, Israel, Israel, Iceland, Hungary, Greece, France, England, Canada, Belgium, USA (unspecified route)
- 28 Sep 2020 No development reported - Phase-III for Fallopian tube cancer (Diagnosis) in United Kingdom, Sweden, Spain, Poland, Norway, Israel, Italy, Hungary, France, Germany, Denmark, Canada, Belgium, Austria (unspecified route)